Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, Escobar MA, Khayat CD, Rusen L, Bensen-Kennedy D, Blackman N, Limsakun T, Veldman A, St Ledger K, Pabinger I; AFFINITY Investigators.

Blood. 2016 Aug 4;128(5):630-7. doi: 10.1182/blood-2016-01-687434. Epub 2016 Jun 21.

2.

The platelet Fc receptor, FcγRIIa.

Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE.

Immunol Rev. 2015 Nov;268(1):241-52. doi: 10.1111/imr.12370. Review.

PMID:
26497525
3.

Current state and novel approaches of antiplatelet therapy.

Metharom P, Berndt MC, Baker RI, Andrews RK.

Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1327-38. doi: 10.1161/ATVBAHA.114.303413. Epub 2015 Apr 2. Review.

4.
5.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF; B-LONG Investigators.

N Engl J Med. 2013 Dec 12;369(24):2313-23. doi: 10.1056/NEJMoa1305074. Epub 2013 Dec 4.

6.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

7.

Micro-ribonucleic Acid 494 regulation of protein S expression.

Tay JW, Romeo G, Hughes QW, Baker RI.

J Thromb Haemost. 2013 Aug;11(8):1547-55. doi: 10.1111/jth.12331.

8.

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.

Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.

PMID:
23432528
9.

Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.

Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, Navarro JC, Ranawaka UK, Uddin W, Ricci S, Gommans J, Schmidt R; VITATOPS trial study group.

Lancet Neurol. 2012 Jun;11(6):512-20. doi: 10.1016/S1474-4422(12)70091-1. Epub 2012 May 2.

10.

Avoiding adverse events with dabigatran by careful selection of eligible patients.

Baker RI, Harper P, McLintock C.

Med J Aust. 2012 Apr 16;196(7):431-2. No abstract available.

PMID:
22509863
11.

Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke.

Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK.

Stroke. 2011 Feb;42(2):498-500. doi: 10.1161/STROKEAHA.110.602532. Epub 2010 Dec 30.

12.

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study.

Fiessinger JN, Bounameaux H, Cairols MA, Clement DL, Coccheri S, Fletcher JP, Hoffmann U, Turpie AG; TAIPAD investigators.

J Thromb Haemost. 2010 Nov;8(11):2369-76. doi: 10.1111/j.1538-7836.2010.04020.x.

13.
14.

Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.

Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.

Haemophilia. 2010 Jul 1;16(4):615-24. doi: 10.1111/j.1365-2516.2010.02206.x. Epub 2010 Mar 16.

PMID:
20331755
15.

Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.

Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI.

Br J Haematol. 2010 May;149(4):625-8. doi: 10.1111/j.1365-2141.2010.08092.x. Epub 2010 Feb 8. No abstract available.

PMID:
20148887
16.

A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders.

Dunkley SM, Russell SJ, Rowell JA, Barnes CD, Baker RI, Sarson MI, Street AM; Australian Haemophilia Centre Directors' Organisation.

Med J Aust. 2009 Oct 19;191(8):460-3.

PMID:
19835544
17.

A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency.

Hooper AJ, Robertson K, Ng L, Kattampallil JS, Latchem D, Willsher PC, Thom J, Baker RI, Burnett JR.

Clin Chim Acta. 2009 Nov;409(1-2):136-9. doi: 10.1016/j.cca.2009.08.017. Epub 2009 Aug 31.

PMID:
19723515
18.

Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura.

Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI.

J Thromb Haemost. 2008 Jul;6(7):1175-82. doi: 10.1111/j.1538-7836.2008.03016.x. Epub 2008 Jul 1.

19.

C-reactive protein in ischemic stroke and its etiologic subtypes.

Eikelboom JW, Hankey GJ, Baker RI, McQuillan A, Thom J, Staton J, Cole V, Yi Q.

J Stroke Cerebrovasc Dis. 2003 Mar-Apr;12(2):74-81.

PMID:
17903908
20.

Polymorphisms in the tissue factor pathway inhibitor gene are not associated with ischaemic stroke.

Sayer MS, Cole VJ, Adams MJ, Baker RI, Staton JM.

Blood Coagul Fibrinolysis. 2007 Oct;18(7):703-8.

PMID:
17890962
Items per page

Supplemental Content

Loading ...
Write to the Help Desk